Coronary Artery Disease
Conditions
Keywords
DES, SDF, MACE, SYNERGY
Brief summary
Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis. This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.
Detailed description
All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.
Interventions
None listed
Sponsors
University of Freiburg
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1.Patient treated by everolimus-eluting SYNERGY® stent
Exclusion criteria
1\. Patient or legal guardian won't give consent to use collected data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MACE | at 12 month follow up | 12-month device-oriented MACE (dMACE) as defined by ARC (cardiac death, MI and TLR). |
Countries
Switzerland
Outcome results
None listed